TheraRadar
← Back
Data updated: Jun 28, 2026

PRAXGEN

Generics

PRAXGEN is a generic drug manufacturer focused on Oncology, Infectious Disease.

2019
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

PRAXGEN's Key Drugs

PRAXGEN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PRAXGEN's Recent FDA Approvals

New NDA/BLA approvals for PRAXGEN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PRAXGEN's Therapeutic Areas

PRAXGEN's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 50%
1 drugs
Infectious Disease 50%
1 drugs

PRAXGEN's Top Competitors

PRAXGEN's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PRAXGEN Pipeline Snapshot

Active clinical trials for PRAXGEN across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling